Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 758-infections-female-reproductive-system-with-cc
    Ask Trek AI about this page

    Infections, Female Reproductive System with CC: Inpatient Reimbursement Overview

    DRG 758 encompasses infections of the female reproductive system with a Complication or Comorbidity and denotes a higher complexity inpatient cohort. Understanding this Diagnosis-Related Group is important for Medicare inpatient reimbursement because it influences the Centers for Medicare & Medicaid Services payment and hospital case-mix classification.

    Customize your policy alerts

    Sign up for drg 758 policy alerts

    Get alerted when payer policies referencing 758 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 758 Overview

    DRG 758 covers inpatient admissions for infections of the female reproductive system that involve a Complication or Comorbidity. This Diagnosis-Related Group groups cases with increased resource needs compared with uncomplicated infections, reflecting higher clinical complexity and longer expected care. It matters for Medicare payment because it determines the bundled payment rate used by the Centers for Medicare & Medicaid Services for hospital reimbursement. Accurate assignment affects hospital revenue and reporting of inpatient case mix.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute antimicrobial strategy trials: randomized or pragmatic trials comparing different initial inpatient antimicrobial regimens, durations, or routes (intravenous versus early oral stepdown) for severe or complicated infections of the female reproductive tract (e.g., tubo-ovarian abscess, severe pelvic inflammatory disease, endometritis with systemic signs). These studies enroll hospitalized reproductive-age and peripartum patients with clinical or radiographic evidence of deep pelvic infection to define protocols that optimize early source control and antimicrobial effectiveness while reducing complications. Results are directly relevant to hospital clinicians and payers because they inform length of stay, use of high-cost IV therapy, and readmission risk, all of which drive inpatient reimbursement and resource utilization for DRG 758 cases.
    • Comparative effectiveness and diagnostic strategy studies: prospective cohort studies or randomized trials comparing diagnostic pathways (e.g., use of advanced imaging, biomarkers, or point-of-care tests) and interventional approaches (image-guided drainage versus surgical source control) for complex gynecologic infections. These trials focus on heterogeneous adult female populations including adolescents and postpartum patients where distinguishing abscess requiring drainage from medically managed infection is uncertain. Findings help clinicians select cost-effective diagnostic algorithms and procedural timing, influencing procedure rates, complication profiles, and reimbursement coding complexity important to providers and payers managing DRG 758 admissions.
    • Post-discharge outcomes and care-transition research: observational studies and implementation trials evaluating post-hospital follow-up models, outpatient antibiotic stewardship, and recurrence prevention strategies among patients discharged after inpatient treatment for female reproductive system infections. These studies target discharged patients across reproductive ages—including those with comorbidities or social vulnerabilities—to measure readmission rates, adherence to outpatient regimens, and long-term fertility or pelvic pain outcomes. Evidence from this research informs care pathways that reduce readmissions, optimize post-acute resource use, and support bundled payment or case-rate negotiations relevant to DRG 758 reimbursement and quality metrics.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.